尊龙凯时
About us
尊龙凯时:Our Values
尊龙凯时:Development Milestone
Products
尊龙凯时:Product List for API
尊龙凯时:Recommended API
尊龙凯时:Product list for Chemicals and Intermediates
Product list for Chemicals and Intermediates
News
尊龙凯时:Contract Manufacturing
尊龙凯时:API and Pharmaceutical Intermediates
尊龙凯时:OTC and Generics
尊龙凯时:Investor Relation
尊龙凯时:PERIODIC REPORT
尊龙凯时:INTERIM REPORT
尊龙凯时:INVESTORS SERVICE
尊龙凯时:Contact Us
About us
News
尊龙凯时:Investor Relation
Products
尊龙凯时:Contract Manufacturing
尊龙凯时:Contact Us
Investor Relation
Investor Relation
尊龙凯时:PERIODIC REPORT
尊龙凯时:INTERIM REPORT
尊龙凯时:INVESTORS SERVICE
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2025
2025-02-05
Overseas Regulatory Announcement-Announcement on Empagliflozin Tablets (10mg) Having Obtained the Drug Registration Certificate
2025-01-21
Overseas Regulatory Announcement-Announcement on Having Obtained the Notification of Approval of Supplementary Drug Application and Other Relevant Information
2025-01-21
Overseas Regulatory Announcement-Announcement on Having Obtained the Notification of Approval of Supplementary Drug Application and Other Relevant Information
2025-01-20
Next Day Disclosure Returns
2025-01-14
Overseas Regulatory Announcement-Announcement in Connection with Tramadol Hydrochloride Sustained-release Tablets Passing the Generic Drugs Consistency Evaluation
2025-01-10
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 2024
2025-01-02
Renewal of Continuing Connected Transaction In Relation To Trademark Licence Agreement
2024-12-31
Inside Information Announcement-Entering into Acquisition Letter of Intent in Relation to the Acquisition of A Company
2024-12-09
Poll Results of the Extraordinary General Meeting
2024-12-06
<
1
2
3
4
5
6
7
...
>